Organization
Collegeville, PA
10 abstracts
Abstract
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.Org: University of Paris-Saclay, Peter MacCallum Cancer Centre, Melbourne, Australia, National Cancer Center Hospital East, Kashiwa, Japan, Vall d’Hebron University Hospital/VHIO, Barcelona, Spain,
Abstract
Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial.Org: Copenhagen University Hospital, Washington University School of Medicine, ModernaTX, Rigshospitalet, Nordic Society of Gynaecologic Oncology–Clinical Trial Unit,
Abstract
Patient-reported outcomes (PROs) among men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 3 study (TALAPRO-2).Org: Huntsman Cancer Institute, University of Utah, Medical Oncology Group, Peter MacCallum Cancer Centre, Melbourne, Australia, Sir Peter MacCallum Department of Oncology,
Abstract
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.Org: Lungen Clinic Grosshansdorf, Airway Research Center North (ARCN), German Center of Lung Research (DZL), Grosshansdorf, Servicio de Oncología Médica, Hospital Universitario de Jaén, European Institute of Oncology,
Abstract
Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study.Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Melbourne, Australia, Australian Catholic University, Institut Gustave Roussy, University of Paris-Saclay,
Abstract
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SEQUENTIAL-DOSE STUDY OF THE SAFETY OF APRATASTAT (TMI-005), A NOVEL ORAL DUAL INHIBITOR OF TNF-ALPHA-CONVERTING ENZYME/METALLOPROTEINASE, IN PATIENTS WITH RHEUMATOID ARTHRITIS ON A BACKGROUND OF METHOTREXAOrg: Research Center for Health Policy and Economics, Radiant Research, Dallas, Altoona Center for Clinical Research, Duncansville, Duncansville,
Abstract
ASSESSMENT OF FUNCTIONAL STATUS AMONG PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS IN A DOUBLE-BLIND TRIAL OF ETANERCEPT AND METHOTREXATE, ALONE AND COMBINED (TEMPO TRIAL)Org: GHOA, Wyeth Research, Collegeville, PA, United States Army Research Institute of Environmental Medicine, Rheumatology, Society of Patients with Rheumatism, Cracow, Poland,
Abstract
ASSESSMENT OF TREATMENT SATISFACTION AMONG PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS IN A DOUBLE-BLIND TRIAL OF ETANERCEPT AND METHOTREXATE, ALONE AND COMBINED (TEMPO TRIAL)Org: GHOA, Wyeth Research, Collegeville, PA, United States Army Research Institute of Environmental Medicine, Rheumatology, Society of Patients with Rheumatism, Cracow, Poland,
Abstract
AUTOANTIBODIES ASSOCIATED WITH ETANERCEPT ARE TRANSIENT, OF LOW TITRES, AND HAVE NO MEASURABLE IMPACT ON CLINICAL OUTCOMESOrg: Clinical Research and Development, Wyeth-Ayerst Research, Philadelphia, United States, Wyeth, Collegeville, PA, United States Army Research Institute of Environmental Medicine,
Abstract
Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkersOrg: University of Cambridge, Cambridge University Hospitals NHS Foundation Trust, UK University Hospital Gasthuisberg, Leuven Cancer Institute, Belgium Botnar Research Centre,